Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre-exposure COVID-19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients

Author Identifier (ORCID)

Wai H. Lim: https://orcid.org/0000-0002-3410-3572

Abstract

The COVID-19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®-treated recipients experienced moderate to severe COVID-19 infection, with two deaths from COVID-19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.

Document Type

Journal Article

Date of Publication

11-1-2025

Volume

55

Issue

11

PubMed ID

41014276

Publication Title

Internal Medicine Journal

Publisher

Wiley

School

School of Medical and Health Sciences

RAS ID

88186

Funders

AstraZeneca

Comments

Lim, W. H., Wang, J., Pilmore, H., McGinn, S., Krishnan, A., Teixeira‐Pinto, A., Kieu, A., Ng, O., & Wong, G. (2025). Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients. Internal Medicine Journal, 55(11), 1944–1949. https://doi.org/10.1111/imj.70179

Copyright

subscription content

First Page

1944

Last Page

1949

Link to Full Text

Share

 
COinS
 

Link to publisher version (DOI)

10.1111/imj.70179